Autologous Bone Marrow Transplantation in Relapses of Chemotherapy-Sensitive Aggressive Non-Hodgkin's Lymphoma: Long-Term Outcome
Authors: Lalle, M.; Montuoro, A.
Source: Journal of Chemotherapy, Volume 12, Number 5, 2000 , pp. 431-434(4)
Publisher: Maney Publishing
Abstract:Eleven patients with relapsed intermediate to high grade non-Hodgkin's lymphoma (NHL) responding to induction treatment were treated with high-dose chemotherapy (CBV or ICBV conditioning regimen) plus autologous bone marrow transplantation as early consolidation treatment. At 6 years, relapse-free survival is 27.3% and overall survival is 36.4%. Patients with bone marrow involvement from NHL before the induction therapy did not have a worse prognosis. Despite the long-term follow-up, no secondary myelodysplasia or acute leukemia occurred in our patients. Within the limitations of patient number and selection, our retrospective study confirms the importance of tumor responsiveness and long-term follow-up. Patients with relapsed, but chemotherapy-sensitive NHL can achieve prolonged survival after high-dose chemotherapy plus autologous bone marrow transplantation.
Document Type: Research Article
Publication date: 2000-01-01